Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Fasching

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
Diabetes, Obesity & Metabolism|October 3, 2024
Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care - The countrywide cross-sectional AUSTRO-PROFIT studyHarald Sourij, Kehkishan Azhar, Faisal Aziz, et al.
BMJ Open|April 15, 2025
Interplay of health-related quality of life and comorbidities in people with type 2 diabetes mellitus treated in primary care settings in Austria: a countrywide cross-sectional studyHarald Sourij, Kehkishan Azhar, Faisal Aziz, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2021
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trialCaroline A Peuker, Sarvenaz Yaghobramzi, Corinna Grunert, et al.
Tumour Virus Research|July 27, 2023
Association of two genomic variants with HPV type-specific risk of cervical cancerFinja Seifert, Rieke Eisenblätter, Julia Beckmann, et al.
Clinical Breast Cancer|June 19, 2023
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer PatientsMarie Tzschaschel, Thomas W P Friedl, Fabienne Schochter, et al.
Annals of Surgical Oncology|April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
Clinical Epigenetics|October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification statusPhilipp Jurmeister, Karsten Weber, Sonia Villegas, et al.
Wiener Klinische Wochenschrift|April 8, 2016
[Antihyperglycemic treatment guidelines for diabetes mellitus type 2]Martin Clodi, Heidemarie Abrahamian, Heinz Drexel, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2019
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive studyAurelia Noske, Volker Möbus, Karsten Weber, et al.
Plos Medicine|August 8, 2019
Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysisJames Yarmolinsky, Caroline L Relton, Artitaya Lophatananon, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Diabetes, Obesity & Metabolism|October 3, 2024
Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care - The countrywide cross-sectional AUSTRO-PROFIT studyHarald Sourij, Kehkishan Azhar, Faisal Aziz, et al.
BMJ Open|April 15, 2025
Interplay of health-related quality of life and comorbidities in people with type 2 diabetes mellitus treated in primary care settings in Austria: a countrywide cross-sectional studyHarald Sourij, Kehkishan Azhar, Faisal Aziz, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2021
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trialCaroline A Peuker, Sarvenaz Yaghobramzi, Corinna Grunert, et al.
Tumour Virus Research|July 27, 2023
Association of two genomic variants with HPV type-specific risk of cervical cancerFinja Seifert, Rieke Eisenblätter, Julia Beckmann, et al.
Clinical Breast Cancer|June 19, 2023
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer PatientsMarie Tzschaschel, Thomas W P Friedl, Fabienne Schochter, et al.
Annals of Surgical Oncology|April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
Clinical Epigenetics|October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification statusPhilipp Jurmeister, Karsten Weber, Sonia Villegas, et al.
Wiener Klinische Wochenschrift|April 8, 2016
[Antihyperglycemic treatment guidelines for diabetes mellitus type 2]Martin Clodi, Heidemarie Abrahamian, Heinz Drexel, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2019
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive studyAurelia Noske, Volker Möbus, Karsten Weber, et al.
Plos Medicine|August 8, 2019
Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysisJames Yarmolinsky, Caroline L Relton, Artitaya Lophatananon, et al.
Pageof 12